Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2671 |
Name | transitional cell carcinoma |
Definition | A carcinoma that derives_from transitional epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3995 |
Path | disease disease of cellular proliferation cancer cell type cancer carcinoma transitional cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR3 dec exp FGFR3 wild-type HRAS G12V | AZ8010 | transitional cell carcinoma | decreased response | detail... |
FGFR3 dec exp FGFR3 wild-type HRAS G12V | Fexagratinib | transitional cell carcinoma | resistant | detail... |
FGFR3 S249C FGFR3 over exp | PD173074 | transitional cell carcinoma | sensitive | detail... |
FGFR3 over exp | Fexagratinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 over exp | AZ8010 | transitional cell carcinoma | sensitive | detail... |
FGFR3 dec exp FGFR3 wild-type HRAS G12V | PD173074 | transitional cell carcinoma | resistant | detail... |
NRAS mutant | Trametinib | transitional cell carcinoma | decreased response | detail... |
HRAS mutant | Trametinib | transitional cell carcinoma | resistant | detail... |
FGFR3 mutant | Infigratinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 fusion | Infigratinib | transitional cell carcinoma | sensitive | detail... |
PTEN loss | Everolimus | transitional cell carcinoma | predicted - resistant | detail... |
FGFR1 amp | Buparlisib + Fexagratinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 mutant | Docetaxel + Vofatamab | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 fusion | Docetaxel + Vofatamab | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR1 mutant | Erdafitinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 mutant | Erdafitinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 V555L | Infigratinib | transitional cell carcinoma | resistant | detail... |
FGFR3 V555M FGFR3 L608V | Infigratinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 V555M | Infigratinib | transitional cell carcinoma | resistant | detail... |
FGFR3 R248C | Erdafitinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 S249C | Erdafitinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 G370C | Erdafitinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 Y373C | Erdafitinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 mutant | Nivolumab | transitional cell carcinoma | no benefit | detail... |
FGFR3 mutant | Atezolizumab | transitional cell carcinoma | no benefit | detail... |
FGFR3 fusion | Erdafitinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR2 fusion | Erdafitinib | transitional cell carcinoma | predicted - sensitive | detail... |
HRAS act mut | Tipifarnib | transitional cell carcinoma | predicted - sensitive | detail... |
HRAS mutant | Tipifarnib | transitional cell carcinoma | predicted - sensitive | detail... |
ARID1B inact mut | unspecified immune checkpoint inhibitor | transitional cell carcinoma | not predictive | detail... |
SMARCA4 inact mut | unspecified immune checkpoint inhibitor | transitional cell carcinoma | not predictive | detail... |
SMARCB1 inact mut | unspecified immune checkpoint inhibitor | transitional cell carcinoma | not predictive | detail... |
PBRM1 inact mut | unspecified immune checkpoint inhibitor | transitional cell carcinoma | not predictive | detail... |
ARID2 inact mut | unspecified immune checkpoint inhibitor | transitional cell carcinoma | not predictive | detail... |
TSC1 R500* TSC1 LOH | Buparlisib | transitional cell carcinoma | predicted - sensitive | detail... |
TSC1 S331Efs*10 TSC1 LOH | Buparlisib | transitional cell carcinoma | predicted - sensitive | detail... |
PIK3CA amp TSC1 LOH | Buparlisib | transitional cell carcinoma | predicted - sensitive | detail... |
PTEN LOH | Buparlisib | transitional cell carcinoma | predicted - sensitive | detail... |
PIK3CA H1047R | Buparlisib | transitional cell carcinoma | no benefit | detail... |
PIK3CA E542K TSC1 LOH | Buparlisib | transitional cell carcinoma | no benefit | detail... |
TSC1 Y185* | Buparlisib | transitional cell carcinoma | no benefit | detail... |
TSC1 R424fs | Buparlisib | transitional cell carcinoma | no benefit | detail... |
TSC1 Q516* | Buparlisib | transitional cell carcinoma | no benefit | detail... |
TSC1 inact mut | Sapanisertib | transitional cell carcinoma | no benefit | detail... |
TSC2 inact mut | Sapanisertib | transitional cell carcinoma | no benefit | detail... |
FGFR3 S249C | Pemigatinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 S249C | Futibatinib | transitional cell carcinoma | predicted - sensitive | detail... |
ATM inact mut | Durvalumab + Olaparib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR1 over exp | Rogaratinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 over exp | Rogaratinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 act mut FGFR3 over exp | Rogaratinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR2 mutant | Cetrelimab + Erdafitinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 mutant | Cetrelimab + Erdafitinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 R248C | Dasatinib + PD173074 | transitional cell carcinoma | sensitive | detail... |
FGFR3 R248C | Dasatinib + Infigratinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 S249C PIK3CA E545K | Erdafitinib + Pictilisib | transitional cell carcinoma | sensitive | detail... |
FGFR3 S249C | Erdafitinib + Gefitinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 S249C PIK3CA E545A | Erdafitinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 S249C FGFR3 N540K PIK3CA E545K | Erdafitinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 S249C FGFR3 V553L | Pemigatinib | transitional cell carcinoma | not predictive | detail... |
FGFR3 S249C FGFR3 V555L | Erdafitinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 S249C FGFR3 amp PTEN C136fs | Erdafitinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 fusion | Pemigatinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 act mut | Pemigatinib | transitional cell carcinoma | sensitive | detail... |
FGFR3 S249C FGFR3 V553M FGFR3 V555L | Pemigatinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 S249C FGFR3 M528I FGFR3 V553M | Pemigatinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 S249C FGFR3 N540S | Pemigatinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 Y373C FGFR3 N540K | Pemigatinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 S249C FGFR3 V555L | Pemigatinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR2 R255W FGFR3 S249C FGFR3 V553M FGFR3 K650M | Erdafitinib | transitional cell carcinoma | predicted - resistant | detail... |
FGFR3 fusion | ABSK061 | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR1 M532T | Pembrolizumab + Pemigatinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR3 Y373C | Pembrolizumab + Pemigatinib | transitional cell carcinoma | predicted - sensitive | detail... |
FGFR1 act mut | Derazantinib | transitional cell carcinoma | no benefit | detail... |
FGFR2 act mut | Derazantinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 act mut | Derazantinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 fusion | Derazantinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 act mut | Atezolizumab + Derazantinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 fusion | Atezolizumab + Derazantinib | transitional cell carcinoma | no benefit | detail... |
FGFR3 over exp | Atezolizumab + Rogaratinib | transitional cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00978250 | Phase II | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | Completed | USA | 0 |
NCT01004224 | Phase I | Infigratinib | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | Completed | USA | TUR | NLD | ITA | ISR | FRA | ESP | DEU | AUT | AUS | 4 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | DNK | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
NCT02516241 | Phase III | Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab | Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | 7 |
NCT02573259 | Phase I | PF-06801591 | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | Completed | USA | POL | BGR | 4 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Completed | USA | GBR | ESP | 1 |
NCT02603432 | Phase III | Avelumab | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | Completed | USA | SWE | POL | NZL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT02717156 | Phase II | Pembrolizumab + sEphB4-HSA | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs | Recruiting | USA | 0 |
NCT02736266 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma | Completed | ITA | 0 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
NCT02807636 | Phase III | Atezolizumab + Carboplatin + Gemcitabine Carboplatin + Gemcitabine | The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy | Completed | USA | TUR | SVN | ROU | POL | NLD | ITA | ISR | GRC | GBR | FIN | EST | ESP | CZE | CAN | BRA | BEL | AUS | 17 |
NCT02812420 | Phase I | Durvalumab + Tremelimumab | Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy | Active, not recruiting | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT02872714 | Phase II | Pemigatinib | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | Completed | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | BEL | 1 |
NCT02880345 | Phase 0 | Pembrolizumab | RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy | Withdrawn | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03029832 | Phase II | Atezolizumab Atezolizumab + Vonlerolizumab | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | Terminated | USA | GBR | CAN | BEL | 1 |
NCT03036098 | Phase III | Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer | Active, not recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 9 |
NCT03047213 | Phase II | Sapanisertib | Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | Active, not recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03091660 | Phase III | BCG Tokyo-172 Strain Solution BCG solution | Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03115801 | Phase II | Atezolizumab Nivolumab | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | Terminated | USA | 0 |
NCT03123055 | Phase I | Atezolizumab + Vofatamab | A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22) | Terminated | USA | TUR | SWE | POL | NLD | ITA | HUN | FRA | ESP | DNK | DEU | BEL | 5 |
NCT03179943 | Phase II | Atezolizumab + Guadecitabine | Overcoming Chechkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG | 3 |
NCT03208712 | Phase I | Atezolizumab + Radium Ra 223 dichloride | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy | Terminated | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03219333 | Phase II | Enfortumab vedotin-ejfv | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201) | Completed | USA | NLD | ITA | FRA | ESP | DEU | 2 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03240016 | Phase II | Nab-paclitaxel + Pembrolizumab | Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer | Completed | USA | 0 |
NCT03241173 | Phase Ib/II | INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | 0 |
NCT03264066 | Phase II | Atezolizumab + Cabozantinib | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | Completed | USA | HUN | GBR | DEU | BEL | 1 |
NCT03277352 | Phase Ib/II | Epacadostat + INCAGN01876 + Pembrolizumab | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Terminated | USA | 0 |
NCT03287050 | Phase I | Pembrolizumab | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | Terminated | USA | 0 |
NCT03288545 | Phase I | Atezolizumab + Enfortumab vedotin-ejfv + Pembrolizumab | A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 1 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT03317496 | Phase II | Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | Terminated | USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Completed | FRA | BEL | 0 |
NCT03343613 | Phase I | LY3300054 + LY3381916 LY3381916 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Terminated | USA | ITA | FRA | ESP | DNK | BEL | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
NCT03390504 | Phase III | Pembrolizumab Erdafitinib Docetaxel + Vinflunine | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 8 |
NCT03407976 | Phase Ib/II | Pembrolizumab + Rivoceranib | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Terminated | USA | 0 |
NCT03409458 | Phase Ib/II | Avelumab + Imifoplatin | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) | Completed | USA | CHE | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03419130 | Phase II | Pembrolizumab | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | Withdrawn | USA | 0 |
NCT03425201 | Phase Ib/II | Cabozantinib + Niraparib | Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) | Completed | ESP | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03448718 | Phase II | Olaparib | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | Completed | USA | 0 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Active, not recruiting | USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL | 2 |
NCT03451331 | Phase II | Carboplatin + Gemcitabine + Nivolumab Gemcitabine + Nivolumab + Oxaliplatin | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT03472560 | Phase II | Avelumab + Axitinib | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | Terminated | USA | POL | ITA | HUN | ESP | 3 |
NCT03473743 | Phase Ib/II | Cetrelimab + Erdafitinib | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations | Active, not recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | BRA | BEL | 4 |
NCT03474107 | Phase III | Enfortumab vedotin-ejfv Docetaxel + Paclitaxel + Vinflunine | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | ARG | 5 |
NCT03486197 | Phase II | Pembrolizumab | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma | Terminated | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03523572 | Phase I | Nivolumab + Trastuzumab deruxtecan | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | Unknown status | USA | ITA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03528694 | Phase III | BCG solution + Durvalumab BCG solution | Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | Active, not recruiting | POL | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 2 |
NCT03534804 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) | Completed | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03547973 | Phase II | Sacituzumab govitecan-hziy | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer | Recruiting | USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU | 1 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03606174 | Phase II | Nivolumab + Sitravatinib | Sitravatinib and Nivolumab in Urothelial Carcinoma Study | Terminated | USA | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Completed | USA | 0 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | AUS | 0 |
NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Completed | USA | 0 |
NCT03674424 | Phase II | Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine | Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) | Active, not recruiting | FRA | BEL | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03679767 | Phase II | Retifanlimab | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Completed | USA | ROU | POL | ITA | HUN | FRA | ESP | AUT | 0 |
NCT03682289 | Phase II | Ceralasertib + Olaparib Olaparib | Phase II Trial of AZD6738 Alone and in Combination With Olaparib | Recruiting | USA | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03744793 | Phase II | Avelumab + Pemetrexed Disodium | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03758781 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Completed | USA | 0 |
NCT03785925 | Phase II | Nivolumab + NKTR-214 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10) | Completed | USA | TUR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BEL | AUS | ARG | 3 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03836352 | Phase II | Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03854474 | Phase Ib/II | Pembrolizumab + Tazemetostat | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | Active, not recruiting | USA | CAN | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03915405 | Phase I | Avelumab + KHK2455 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Terminated | USA | ESP | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
NCT03973333 | Phase Ib/II | Atezolizumab + IMC-C103C IMC-C103C | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Withdrawn | USA | GBR | ESP | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03989362 | Phase II | Ipilimumab + Vopratelimab | Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE) | Completed | USA | CAN | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03992131 | Phase Ib/II | Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Terminated | USA | 0 |
NCT04003610 | Phase II | Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | Terminated | USA | SVK | ROU | POL | ITA | IRL | GBR | FRA | FIN | ESP | DEU | CAN | BEL | AUT | 2 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Recruiting | USA | ESP | CAN | BEL | 0 |
NCT04095273 | Phase I | Elimusertib + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | CHE | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04149574 | Phase III | BCG solution + Nivolumab BCG solution | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) | Terminated | USA | SWE | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 3 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | SVK | AUS | 2 |
NCT04158700 | Phase Ib/II | LY3200882 + Pembrolizumab | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | Withdrawn | USA | FRA | ESP | 0 |
NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Active, not recruiting | FRA | 0 |
NCT04173338 | Phase I | Cabozantinib + Pemetrexed Disodium | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | Terminated | USA | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04200963 | Phase I | KYN-175 | KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | Completed | USA | 0 |
NCT04223856 | Phase III | Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab | Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUS | ARG | 7 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Completed | USA | GBR | ESP | DEU | 1 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Terminated | USA | NZL | ITA | 0 |
NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT04349280 | Phase I | Bintrafusp alfa | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | Terminated | USA | NLD | FRA | ESP | CAN | 0 |
NCT04383938 | Phase Ib/II | APR-246 + Pembrolizumab | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04452214 | Phase I | Nidanilimab + Pembrolizumab | A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors | Completed | USA | 0 |
NCT04486781 | Phase II | Pembrolizumab + sEphB4-HSA | A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | Recruiting | USA | 0 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04501094 | Phase II | Bintrafusp alfa | A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma | Terminated | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04527991 | Phase III | Paclitaxel Docetaxel Vinflunine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) | Active, not recruiting | USA | TUR | SWE | ITA | ISR | IRL | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | 8 |
NCT04543110 | Phase II | Durvalumab | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT) | Recruiting | CAN | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04565275 | Phase Ib/II | ICP-192 | A Study of ICP-192 in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT04579224 | Phase III | Sacituzumab govitecan-hziy Eribulin Gemcitabine Eribulin + Gemcitabine Docetaxel Paclitaxel | Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Recruiting | USA | 0 |
NCT04586244 | Phase II | Retifanlimab Epacadostat + Retifanlimab Epacadostat | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (Optimus) | Terminated | USA | ITA | FRA | 0 |
NCT04601402 | Phase I | Avelumab + GEN-001 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | Completed | USA | 0 |
NCT04601857 | Phase II | Futibatinib + Pembrolizumab | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | Active, not recruiting | USA | FRA | ESP | 0 |
NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | FRA | ESP | CAN | 0 |
NCT04701918 | Phase II | Pembrolizumab | Pembrolizumab And Cryoablation In Urothelial Carcinoma | Recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
NCT04819373 | Phase II | EIK1001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Terminated | USA | POL | GBR | FRA | ESP | 0 |
NCT04856189 | Phase Ib/II | Pembrolizumab + Selinexor | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | Recruiting | USA | 0 |
NCT04863885 | Phase Ib/II | Ipilimumab + Nivolumab + Sacituzumab govitecan-hziy | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | Active, not recruiting | USA | 0 |
NCT04871529 | Phase II | Avelumab + Carboplatin + Gemcitabine | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) | Suspended | USA | 0 |
NCT04878029 | Phase I | Cabozantinib + Enfortumab vedotin-ejfv | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | Recruiting | USA | 0 |
NCT04879329 | Phase II | Disitamab vedotin Disitamab vedotin + Pembrolizumab | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Recruiting | USA | ITA | ISR | GBR | ESP | CAN | BEL | AUS | ARG | 2 |
NCT04887831 | Phase II | Cisplatin + Gemcitabine + Trilaciclib Avelumab + Trilaciclib Carboplatin + Gemcitabine + Trilaciclib Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Gemcitabine | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3) | Terminated | USA | HUN | FRA | ESP | 1 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04936230 | Phase II | Atezolizumab | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | Terminated | USA | 0 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT04999202 | Phase I | BAY2416964 + Pembrolizumab BAY2416964 | A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults | Active, not recruiting | USA | ITA | GBR | 1 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05014139 | Phase I | Enfortumab vedotin-ejfv | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05102214 | Phase Ib/II | HLX301 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05107427 | Phase II | Avelumab + MRx0518 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma (AVENU) | Withdrawn | USA | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Terminated | USA | 0 |
NCT05154994 | Phase I | Belinostat + Durvalumab + Tremelimumab | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE) | Suspended | USA | 0 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05219435 | Phase II | Ipilimumab + Nivolumab | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) | Recruiting | ESP | 0 |
NCT05226117 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | Unknown status | ITA | 0 |
NCT05229614 | Phase II | Pembrolizumab | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) | Recruiting | ITA | DEU | 0 |
NCT05233436 | Phase I | PF-07265028 PF-06801591 + PF-07265028 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | Terminated | USA | 1 |
NCT05244551 | Phase I | ABSK061 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT05327530 | Phase II | Avelumab Avelumab + NKTR-255 Avelumab + Sacituzumab govitecan-hziy Avelumab + M6223 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | Active, not recruiting | USA | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05335941 | Phase II | Etrumadenant + Pemetrexed Disodium + Zimberelimab | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05354323 | Phase I | NECVAX-NEO1 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | Recruiting | LTU | 0 |
NCT05394337 | Phase I | Tiragolumab Atezolizumab | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05397171 | Phase Ib/II | AZD8853 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | Terminated | USA | CAN | 0 |
NCT05524545 | Phase I | Enfortumab vedotin-ejfv + Evorpacept | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | Recruiting | USA | 0 |
NCT05535218 | Phase II | Pembrolizumab + Sacituzumab govitecan-hziy | Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer (SURE-02) | Enrolling by invitation | ITA | 0 |
NCT05544552 | Phase Ib/II | TYRA-300 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301) | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT05548296 | Phase Ib/II | Prexasertib Gemcitabine + Prexasertib | A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05574504 | Phase II | Avelumab + Lurbinectedin | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | Withdrawn | USA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05600127 | Phase II | Avelumab | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer (CHASIT) | Recruiting | NLD | 0 |
NCT05614739 | Phase I | LOXO-435 + Pembrolizumab LOXO-435 | A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3 | Recruiting | USA | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05627063 | Phase I | ABSK121 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05642780 | Phase II | Pembrolizumab + SKB264 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Recruiting | USA | POL | CAN | BEL | AUS | 1 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05645692 | Phase II | Atezolizumab RO7247669 RO7247669 + Tiragolumab | A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer | Active, not recruiting | USA | TUR | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | BRA | AUS | 3 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05687721 | Phase Ib/II | Avelumab + Copanlisib | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | Not yet recruiting | USA | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05733000 | Phase II | CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Recruiting | USA | 0 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | BEL | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05845814 | Phase Ib/II | Enfortumab vedotin-ejfv + MK-4280A Enfortumab vedotin-ejfv + MK-7684A Enfortumab vedotin-ejfv + Pembrolizumab | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05923190 | Phase II | Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv + Pembrolizumab | Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05929235 | Phase I | FX-909 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT06018116 | Phase II | Bicalutamide | A Canadian Phase II Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer (CANUCK-01) | Withdrawn | CAN | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT06036121 | Phase I | ADRX-0706 | A Study of ADRX-0706 in Select Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06225596 | Phase II | Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | ARG | 5 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06285097 | Phase I | PF-07820435 PF-06801591 + PF-07820435 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 2 |
NCT06293898 | Phase I | BL-M07D1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Recruiting | USA | 0 |
NCT06305767 | Phase II | Pembrolizumab mRNA-4157 + Pembrolizumab | A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005) | Recruiting | USA | TUR | SWE | POL | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT06318871 | Phase I | CIML-NK cells + Nogapendekin alfa inbakicept | A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | Recruiting | USA | 0 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
NCT06332755 | Phase I | LB-LR1109 | Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) | Recruiting | USA | 0 |
NCT06424717 | Phase II | Avelumab + M1774 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | Withdrawn | 0 | |
NCT06448364 | Phase I | PF-06801591 + PF-07329640 PF-07329640 Bevacizumab + PF-07329640 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR) | Terminated | USA | 1 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06483334 | Phase Ib/II | Enfortumab vedotin-ejfv + Pembrolizumab + Sacituzumab govitecan-hziy Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | Recruiting | USA | NLD | ISR | GBR | ESP | CAN | 2 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06534983 | Phase II | Nivolumab Autogene cevumeran + Nivolumab | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) (IMCODE004) | Recruiting | USA | ITA | DEU | CAN | AUS | 0 |
NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Recruiting | USA | 0 |
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |
NCT06644755 | Phase I | DS-2243a | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |
NCT06697197 | Phase Ib/II | BMS-986482 + Nivolumab and relatlimab-rmbw Bevacizumab + BMS-986482 BMS-986482 BMS-986298 + BMS-986482 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Not yet recruiting | USA | 0 |